Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Aquestive Therapeutics Inc shares valued at $2,400 were sold by Barber Daniel on Sep 19 ’25. At $6.00 per share, Barber Daniel sold 400 shares. The insider’s holdings dropped to 1,014,773 shares worth approximately $5.34 million following the completion of this transaction.
Also, DANIEL R BARBER purchased 400 shares, netting a total of over 1,976 in proceeds.
Before that, Jung Cassie had sold 62,180 shares from its account. In a trade valued at $310,900, the Chief Operating Officer traded Aquestive Therapeutics Inc shares for $5.00 each. Upon closing the transaction, the insider’s holdings decreased to 62,180 shares, worth approximately $1.49 million.
Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of May 10, 2024, Leerink Partners has initiated its “an Outperform” rating for AQST. Earlier on April 11, 2024, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for AQST stock.
Analyzing AQST Stock Performance
On last trading session, Aquestive Therapeutics Inc [NASDAQ: AQST] plunged -2.95% to $5.26. The stock’s lowest price that day was $5.195, but it reached a high of $5.51 in the same session. During the last five days, there has been a surge of approximately 6.48%. Over the course of the year, Aquestive Therapeutics Inc shares have jumped approximately 7.79%. Shares of the company reached a 52-week high of $6.00 on 09/19/25 and a 52-week low of $2.12 on 05/13/25.
Support And Resistance Levels for Aquestive Therapeutics Inc (AQST)
According to the 24-hour chart, there is a support level at 5.13, which, if violated, would cause prices to drop to 5.01. In the upper region, resistance lies at 5.45. The next price resistance is at 5.64. RSI (Relative Strength Index) is 59.56 on the 14-day chart, showing neutral technical sentiment.
Is Aquestive Therapeutics Inc subject to short interest?
Stocks of Aquestive Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.17 million shares to 9.27 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 9.44 million shares. A decline of -1.81% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.79 of the overall float, the days-to-cover ratio (short ratio) decline to 6.79.
Which companies own the most shares of Aquestive Therapeutics Inc (AQST)?
In terms of Aquestive Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 10 in the next 12 months, up nearly 84.5% from the previous closing price of $5.42. Analysts anticipate Aquestive Therapeutics Inc stock to reach 12 by 2025, with the lowest price target being 7. In spite of this, 3 analysts ranked Aquestive Therapeutics Inc stock as Buy at the end of 2025. On March 28, 2024, Raymond James assigned a price target of “an Outperform” to the stock and initiated coverage with a $7.
